Showing 541-550 of 618 results for "".
- Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunologyhttps://modernod.com/news/aramis-biosciences-launches-to-address-unmet-needs-in-ocular-immunology/2480514/Aramis Biosciences announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in ophthalmic pharmaceuticals. Proceeds from the financing will be used to advance the company’s pipeline, including i
- RxSight Announces Pricing of Initial Public Offeringhttps://modernod.com/news/rxsight-announces-pricing-of-initial-public-offering/2479423/RxSight announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16 per share. The gross proceeds to RxSight from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and
- Surface Ophthalmics Announces $25 Million Private Round of Fundraisinghttps://modernod.com/news/surface-ophthalmics-announces-25-million-private-round-of-fundraising/2479393/Surface Ophthalmics announced it has secured gross proceeds of approximately $25 million in a private placement of preferred stock, at a purchase price of $4.50 per share. Investors in this round of financing included both new and existing investors made up of institutional, healthcare-focused, a
- Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trialshttps://modernod.com/news/dopavision-closes-e12-million-series-a-round-to-advance-digital-childhood-myopia-therapeutic-through-clinical-trials/2479372/Dopavision announced the closing of a €12 million Series A financing round. The proceeds will be used to fund the clinical development of MyopiaX, the company’s lead product in childhood myopia, with the goal to demonstrate its safety and efficacy in clinical studies and advance this innova
- Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticalshttps://modernod.com/news/oxford-finance-provides-125-million-credit-facility-to-kala-pharmaceuticals/2479229/Oxford Finance has announced the closing of a $125 million senior secured term loan with Kala Pharmaceuticals. Proceeds from the transaction will be used to refinance existing indebtedness and provide additional growth capital for the company’s marketing of its two approved ophthalmic products.</
- Oculis Announces Financing to Advance Topical Therapies for Posterior and Anterior Segmentshttps://modernod.com/news/oculis-announces-financing-to-advance-therapies-for-anterior-segment/2479162/Oculis announced that it has closed an oversubscribed $57 million Series C financing. Proceeds from this financing will accelerate Oculis’ strategy with the aim of delivering key goals in the near-term to drive shareholder value and bring transformative therapies to patients. The
- AffaMed Therapeutics Completes $170 Million Series B Financing to Further Development of Ophthalmic and Neuroscience Pipelinehttps://modernod.com/news/affamed-therapeutics-completes-170-million-series-b-financing-to-further-development-of-ophthalmic-and-neuroscience-pipeline/2479029/AffaMed Therapeutics announced the completion of over $170 million in Series B financing. Proceeds from the financing will be used to advance clinical development of AffaMed’s pipeline of innovative therapeutic candidates, progress business development and partnering activities, and support
- GSK, Vir Biotechnology Move Anti-SARS-CoV-2 Monoclonal Antibody Into Phase 3https://modernod.com/news/gsk-vir-biotechnology-move-anti-sars-cov-2-monoclonal-antibody-into-phase-3/2478385/GlaxoSmithKline and partner Vir Biotechnology announced that the COMET-ICE study evaluating VIR-7831 as an early treatment for COVID-19 patients deemed to be at high risk of hospitalization will proceed into phase 3 testing, with preliminary results coming possibly before the end of this year. Th
- Sight Sciences Announces $30 Million Financinghttps://modernod.com/news/sight-sciences-announces-30-million-financing/2477405/Sight Sciences announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and operational development and to support commercial expansion for Sight Sciences’ OMN
- Ocuphire Pharma Raises Over $5 Million to Complete Late Phase 2 Clinical Trials for Ophthalmic Disordershttps://modernod.com/news/ocuphire-pharma-raises-over-5-million-to-complete-late-phase-2-clinical-trials-for-ophthalmic-disorders/2476760/Ocuphire Pharma announced that it has closed on over $5 million of financing. Proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol. Nyxol is a novel eye drop treatment for multiple front-of-the-eye disorders, including night vision distur